Randomized Trial for Non-small Cell Lung Cancer after Progression on EGFR TKI
- Trial ID:
- IRB-22-7988
- Michael P. Kosty, M.D.
Inclusion Criteria
Patients must:
- Have EGFR-mutated Non-small Cell Lung Cancer.
Have disease progression while receiving a third-generation EGFR TKI (such as Tagrisso).
Be ambulatory and able to carry out work of a light or sedentary nature. For example, must be capable of performing light housework or office work.
Be willing to provide tumor tissue by either a new tumor biopsy or from a previous biopsy performed on or after treatment with EGFR TKI.
Exclusion Criteria
Patients must not:
- Have received other prior systemic cancer therapies (including chemotherapy, immunotherapy, etc) since being diagnosed with metastatic or locally advanced disease.
Have clinically active brain metastases or spinal cord compression.
Have a history of interstitial lung disease, severe respiratory compromise, or significant cardiovascular disease.
Be pregnant or nursing.
Additional Info
All physician visits and study treatments will occur at Scripps Clinic Torrey Pines (Geisel Pavilion) and Scripps MD Anderson Prebys Cancer Center.Participation in the study will last for up to 49 months.
Search for NCT05338970 on https://clinicaltrials.gov/ for additional information.
Contact Info:
- Clinical Research Services
- CRSLeadership@scrippshealth.org